Peter Alan Lacey Sells 96,464 Shares of Hemostemix Inc. (CVE:HEM) Stock

Hemostemix Inc. (CVE:HEM) Director Peter Alan Lacey sold 96,464 shares of the stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of C$0.18, for a total value of C$16,881.20.

Hemostemix Trading Up 12.5 %

Hemostemix stock opened at C$0.18 on Friday. Hemostemix Inc. has a one year low of C$0.04 and a one year high of C$0.43. The business’s fifty day moving average is C$0.21 and its 200 day moving average is C$0.12. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock has a market capitalization of C$26.23 million, a PE ratio of -5.25 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.